Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serratia marcescens enzyme-2 (SME-2) is a chromosomally encoded Ambler Class A carbapenemase primarily found in the Gram-negative bacterium Serratia marcescens (Queenan & Bush, 2007). This enzyme is a significant factor in antibiotic resistance, as it efficiently hydrolyzes carbapenems, which are considered last-line treatments for multi-drug resistant infections (Naas et al., 1994). SME-2 operates through a serine-based mechanism, where a nucleophilic serine residue in the active site attacks and opens the beta-lactam ring, rendering the antibiotic inactive (Walther-Rasmussen & Hoiby, 2007). Unlike many other Class A carbapenemases like KPC, SME-2 is generally susceptible to inhibition by classical inhibitors such as clavulanic acid and tazobactam, as well as newer non-beta-lactam inhibitors like avibactam and vaborbactam (Majewski et al., 2016). The presence of this enzyme in clinical isolates poses a significant therapeutic challenge, necessitating the use of combination therapies to restore antibiotic efficacy (Bush & Bradford, 2016).
Hydrolysis of the beta-lactam ring of carbapenems and other beta-lactams via a catalytic serine residue (Walther-Rasmussen & Hoiby, 2007). Beta-lactamase inhibitors function by binding to the active site and preventing substrate access (Bush & Bradford, 2016).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serratia marcescens enzyme-2 (SME-2) carbapenemase (SME-2).